Teva price target raised to $56 from $50 at Citigroup Citigroup raised its price target for Teva shares to $56 saying the recently launched longer acting version of Copaxone is progressing ahead of expectations. Citi believes the Copaxone switch is being underappreciated and keeps a Buy rating on the stock.
Teva board authorizes increase in share repurchase program to $3B The Company announced today that, as authorized by the Board of Directors, it will increase its share repurchase program by $1.7 billion to $3 billion. The program has no time limitations. The Company intends to begin purchasing shares promptly.